Sign In
22 Dec 2020 08:30
THIS ANNOUNCEMENT, AND THE INFORMATION CONTAINED HEREIN, IS NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO OR FROM THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO.
THE INFORMATION COMMUNICATED WITHIN THIS ANNOUNCEMENT IS DEEMED TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014. UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.
Redx Pharma plc
("Redx" or "the Company")
Admission of Placing, Open Offer and Conversion Shares
&
Directors dealings
Alderley Park, 22 December 2020 Redx Pharma (AIM: REDX), the drug discovery and development company focused on cancer and fibrosis announces that the Admission to trading on AIM ("admission") of the 78,639,800 Placing Shares, Open Offer Shares and Conversion Shares referred to in the Result of General Meeting announcement on 21 December 2020 became effective at 8.00 a.m. this morning.
Following admission of the 78,639,800 new ordinary shares, the Company confirms that it has 273,887,213 ordinary shares of 1p each with voting rights in issue. The Company holds no ordinary shares in treasury. Accordingly, the total number of voting rights in Redx will be 273,887,213, which may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
In addition, the Company confirms that all conditions have been met in relation to the options being granted to Lisa Anson and Richard Armer as announced on 2 December 2020.
Capitalised terms used in this announcement shall, unless defined otherwise, have the same meaning as in the announcement of the Placing and Open Offer made by the Company on 2 December 2020.
For further information, please contact: | |
Redx Pharma Plc | T: +44 1625 469 918 |
Iain Ross, Chairman Lisa Anson, Chief Executive | |
SPARK Advisory Partners (Nominated Adviser) | T: +44 203 368 3550 |
Matt Davis/Adam Dawes | |
WG Partners LLP (Broker) | T: +44 20 3705 9330 |
Claes Spång/Chris Lee/David Wilson | |
FTI Consulting | T: +44 20 3727 1000 |
Simon Conway/Ciara Martin | |
|
About Redx Pharma Plc
Redx Pharma (AIM:REDX) is focused on the discovery and development of novel targeted medicines for the treatment of cancer and fibrotic disease, aiming to progress them to clinical proof of concept. Redx's lead oncology asset, RXC004, is currently in a phase 1 study in patients with advanced malignancies with top line data expected in H1 2021 and the Company's selective ROCK2 inhibitor, RXC007, is expected to enter a phase 1 clinical study in H1 2021.
The Company's core capability of converting medicinal chemistry insights into differentiated and commercially attractive small molecule drug candidates against clinically validated targets has been recognized by others. Over the last three years the company has completed four major preclinical stage deals with AstraZeneca, Jazz Pharmaceuticals and Loxo Oncology (now Eli Lilly).
1. | Details of the person discharging managerial responsibilities/person closely associated | |
a) | Name | Sarah Gordon Wild |
2. | Reason for the notification | |
a) | Position/status | Non-executive director |
b) | Initial notification/Amendment | Initial Notification |
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Redx Pharma Plc |
b) | LEI | 213800HMS4EBXO589Y37 |
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument | Ordinary Shares of 1p each |
b) | Identification code | ISIN: GB00BSNB6S51 |
c) | Nature of the transactions | Participation in Placing and Open Offer |
d) | Price(s) and volume(s) | Price: 56p pence per share Volume: 892,858 shares |
e) | Aggregated information - Aggregated volume - Price | As for d) above |
f) | Date of the transactions | 22 December 2020 |
f) | Place of the transactions | Off-market |
1. | Details of the person discharging managerial responsibilities/person closely associated | |
a) | Name | Lisa Anson |
2. | Reason for the notification | |
a) | Position/status | Chief Executive Officer |
b) | Initial notification/Amendment | Initial Notification |
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Redx Pharma Plc |
b) | LEI | 213800HMS4EBXO589Y37 |
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument | Ordinary Shares of 1p each |
b) | Identification code | ISIN: GB00BSNB6S51 |
c) | Nature of the transactions | Participation in Placing and Open Offer |
d) | Price(s) and volume(s) | Price: 56p pence per share Volume: 89,286 shares |
e) | Aggregated information - Aggregated volume - Price | As for d) above |
f) | Date of the transactions | 22 December 2020 |
f) | Place of the transactions | Off-market |
1. | Details of the person discharging managerial responsibilities/person closely associated | |
a) | Name | Iain Ross |
2. | Reason for the notification | |
a) | Position/status | Non-executive Chairman |
b) | Initial notification/Amendment | Initial Notification |
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Redx Pharma Plc |
b) | LEI | 213800HMS4EBXO589Y37 |
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument | Ordinary Shares of 1p each |
b) | Identification code | ISIN: GB00BSNB6S51 |
c) | Nature of the transactions | Participation in Placing and Open Offer |
d) | Price(s) and volume(s) | Price: 56p pence per share Volume: 35,130 shares |
e) | Aggregated information - Aggregated volume - Price | As for d) above |
f) | Date of the transactions | 22 December 2020 |
f) | Place of the transactions | Off-market |
1. | Details of the person discharging managerial responsibilities/person closely associated | |
a) | Name | Peter Presland |
2. | Reason for the notification | |
a) | Position/status | Non-executive director |
b) | Initial notification/Amendment | Initial Notification |
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Redx Pharma Plc |
b) | LEI | 213800HMS4EBXO589Y37 |
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument | Ordinary Shares of 1p each |
b) | Identification code | ISIN: GB00BSNB6S51 |
c) | Nature of the transactions | Participation in Placing and Open Offer |
d) | Price(s) and volume(s) | Price: 56p pence per share Volume: 27,376 shares |
e) | Aggregated information - Aggregated volume - Price | As for d) above |
f) | Date of the transactions | 22 December 2020 |
f) | Place of the transactions | Off-market |
1. | Details of the person discharging managerial responsibilities/person closely associated | |
a) | Name | Lisa Anson |
2. | Reason for the notification | |
a) | Position/status | Chief Executive Officer |
b) | Initial notification/Amendment | Initial Notification |
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Redx Pharma Plc |
b) | LEI | 213800HMS4EBXO589Y37 |
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument | Options over Ordinary Shares of 1p each |
b) | Identification code | ISIN: GB00BSNB6S51 |
c) | Nature of the transactions | Grant of options under the Redx All Employee Share Option Scheme |
d) | Price(s) and volume(s) | Price: 56p pence per share Volume: 11,683,586 shares |
e) | Aggregated information - Aggregated volume - Price | As for d) above |
f) | Date of the transactions | 22 December 2020 |
f) | Place of the transactions | Off-market |
1. | Details of the person discharging managerial responsibilities/person closely associated | |
a) | Name | Richard Armer |
2. | Reason for the notification | |
a) | Position/status | Chief Scientific Officer |
b) | Initial notification/Amendment | Initial Notification |
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Redx Pharma Plc |
b) | LEI | 213800HMS4EBXO589Y37 |
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument | Options over Ordinary Shares of 1p each |
b) | Identification code | ISIN: GB00BSNB6S51 |
c) | Nature of the transactions | Grant of options under the Redx All Employee Share Option Scheme |
d) | Price(s) and volume(s) | Price: 56p pence per share Volume: 5,984,378 shares |
e) | Aggregated information - Aggregated volume - Price | As for d) above |
f) | Date of the transactions | 22 December 2020 |
f) | Place of the transactions | Off-market |
Follow the stocks
